These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37330416)

  • 1. Covalent-reversible peptide-based protease inhibitors. Design, synthesis, and clinical success stories.
    Feral A; Martin AR; Desfoux A; Amblard M; Vezenkov LL
    Amino Acids; 2023 Dec; 55(12):1775-1800. PubMed ID: 37330416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.
    Awoonor-Williams E; Abu-Saleh AAA
    Phys Chem Chem Phys; 2021 Mar; 23(11):6746-6757. PubMed ID: 33711090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting eukaryotic proteases for natural products-based drug development.
    Al-Awadhi FH; Luesch H
    Nat Prod Rep; 2020 Jun; 37(6):827-860. PubMed ID: 32519686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
    Awoonor-Williams E
    Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Critical Study on Acylating and Covalent Reversible Fragment Inhibitors of SARS-CoV-2 Main Protease Targeting the S1 Site with Pyridine.
    Wamser R; Pach S; Arkona C; Baumgardt M; Aziz UBA; Hocke AC; Wolber G; Rademann J
    ChemMedChem; 2023 May; 18(9):e202200635. PubMed ID: 36812048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advances in Covalent Drug Discovery.
    Schaefer D; Cheng X
    Pharmaceuticals (Basel); 2023 Apr; 16(5):. PubMed ID: 37242447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL
    Alamri MA; Tahir Ul Qamar M; Mirza MU; Bhadane R; Alqahtani SM; Muneer I; Froeyen M; Salo-Ahen OMH
    J Biomol Struct Dyn; 2021 Aug; 39(13):4936-4948. PubMed ID: 32579061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 main protease inhibitors: What is moving in the field of peptides and peptidomimetics?
    Algar-Lizana S; Bonache MÁ; González-Muñiz R
    J Pept Sci; 2023 May; 29(5):e3467. PubMed ID: 36479966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives.
    La Monica G; Bono A; Lauria A; Martorana A
    J Med Chem; 2022 Oct; 65(19):12500-12534. PubMed ID: 36169610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.
    Vázquez-Mendoza LH; Mendoza-Figueroa HL; García-Vázquez JB; Correa-Basurto J; García-Machorro J
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comprehensive Guide for Assessing Covalent Inhibition in Enzymatic Assays Illustrated with Kinetic Simulations.
    Mons E; Roet S; Kim RQ; Mulder MPC
    Curr Protoc; 2022 Jun; 2(6):e419. PubMed ID: 35671150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the Cruzain Cysteine Protease Reversible and Irreversible Covalent Inhibition Mechanism.
    Silva JRA; Cianni L; Araujo D; Batista PHJ; de Vita D; Rosini F; Leitão A; Lameira J; Montanari CA
    J Chem Inf Model; 2020 Mar; 60(3):1666-1677. PubMed ID: 32126170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covalent and non-covalent reversible proteasome inhibition.
    Beck P; Dubiella C; Groll M
    Biol Chem; 2012 Oct; 393(10):1101-20. PubMed ID: 23091276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide length and leaving-group sterics influence potency of peptide phosphonate protease inhibitors.
    Brown CM; Ray M; Eroy-Reveles AA; Egea P; Tajon C; Craik CS
    Chem Biol; 2011 Jan; 18(1):48-57. PubMed ID: 21276938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
    Tsantrizos YS
    Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible covalent inhibitors suppress enterovirus 71 infection by targeting the 3C protease.
    Liu M; Xu B; Ma Y; Shang L; Ye S; Wang Y
    Antiviral Res; 2021 Aug; 192():105102. PubMed ID: 34082057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Covalent Inhibition in Drug Discovery: Filling the Void in Literature.
    Bjij I; Olotu FA; Agoni C; Adeniji E; Khan S; El Rashedy A; Cherqaoui D; Soliman MES
    Curr Top Med Chem; 2018; 18(13):1135-1145. PubMed ID: 30068277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs).
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105422. PubMed ID: 33434619
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.